The intracellular signalosome of PD-L1 in cancer cells

被引:207
作者
Escors, David [1 ,2 ]
Gato-Canas, Maria [1 ]
Zuazo, Miren [1 ]
Arasanz, Hugo [1 ,3 ]
Jesus Garcia-Granda, Maria [1 ]
Vera, Ruth [3 ]
Kochan, Grazyna [1 ]
机构
[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain
[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England
[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain
关键词
T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;
D O I
10.1038/s41392-018-0022-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
引用
收藏
页数:9
相关论文
共 113 条
  • [71] Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
    Nakanishi, Juro
    Wada, Yoshihiro
    Matsumoto, Koichiro
    Azuma, Miyuki
    Kikuchi, Ken
    Ueda, Shoichi
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) : 1173 - 1182
  • [72] PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
    Nghiem, Paul T.
    Bhatia, Shailender
    Lipson, Evan J.
    Kudchadkar, Ragini R.
    Miller, Natalie J.
    Annamalai, Lakshmanan
    Berry, Sneha
    Chartash, Elliot K.
    Daud, Adil
    Fling, Steven P.
    Friedlander, Philip A.
    Kluger, Harriet M.
    Kohrt, Holbrook E.
    Lundgren, Lisa
    Margolin, Kim
    Mitchell, Alan
    Olencki, Thomas
    Pardoll, Drew M.
    Reddy, Sunil A.
    Shantha, Erica M.
    Sharfman, William H.
    Sharon, Elad
    Shemanski, Lynn R.
    Shinohara, Michi M.
    Sunshine, Joel C.
    Taube, Janis M.
    Thompson, John A.
    Townson, Steven M.
    Yearley, Jennifer H.
    Topalian, Suzanne L.
    Cheever, Martin A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) : 2542 - 2552
  • [73] Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells
    Noh, Hyangsoon
    Hu, Jiemiao
    Wang, Xiaohong
    Xia, Xueqing
    Satelli, Arun
    Li, Shulin
    [J]. CELL COMMUNICATION AND SIGNALING, 2015, 13
  • [74] PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
    Noman, Muhammad Zaeem
    Desantis, Giacomo
    Janji, Bassam
    Hasmim, Meriem
    Karray, Saoussen
    Dessen, Philippe
    Bronte, Vincenzo
    Chouaib, Salem
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (05) : 781 - 790
  • [75] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [76] Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
    Ota, Keiichi
    Azuma, Koichi
    Kawahara, Akihiko
    Hattori, Satoshi
    Iwama, Eiji
    Tanizaki, Junko
    Harada, Taishi
    Matsumoto, Koichiro
    Takayama, Koichi
    Takamori, Shinzo
    Kage, Masayoshi
    Hoshino, Tomoaki
    Nakanishi, Yoichi
    Okamoto, Isamu
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (17) : 4014 - 4021
  • [77] Glucose metabolism regulatesT cell activation, differentiation, and functions
    Palmer, Clovis S.
    Ostrowski, Matias
    Balderson, Brad
    Christian, Nicole
    Crowe, Suzanne M.
    [J]. FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [78] Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model
    Park, Younghee
    Park, Ji Min
    Kim, Dan Hyo
    Kwon, Jeanny
    Kim, In Ah
    [J]. ONCOTARGET, 2017, 8 (66) : 110392 - 110405
  • [79] Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    Parsa, Andrew T.
    Waldron, James S.
    Panner, Amith
    Crane, Courtney A.
    Parney, Ian F.
    Barry, Jeffrey J.
    Cachola, Kristine E.
    Murray, Joseph C.
    Tihan, Tarik
    Jensen, Michael C.
    Mischel, Paul S.
    Stokoe, David
    Pieper, Russell O.
    [J]. NATURE MEDICINE, 2007, 13 (01) : 84 - 88
  • [80] PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
    Patsoukis, Nikolaos
    Bardhan, Kankana
    Chatterjee, Pranam
    Sari, Duygu
    Liu, Bianling
    Bell, Lauren N.
    Karoly, Edward D.
    Freeman, Gordon J.
    Petkova, Victoria
    Seth, Pankaj
    Li, Lequn
    Boussiotis, Vassiliki A.
    [J]. NATURE COMMUNICATIONS, 2015, 6